Harnessing the Hippo–YAP pathway for women's health
We are developing therapeutics that target the Hippo/YAP signaling pathway — a central regulator of the female reproductive tract — for gynecological cancers and fertility preservation.
A shared driver across the reproductive tract
The Hippo/YAP pathway controls how cells grow, survive, and respond to their surroundings. In the ovary, fallopian tube, and cervix, its disruption can drive cancer — while healthy YAP signaling is essential for normal follicle development.
That makes it a single biological lever with several therapeutic applications, which we are pursuing in three programs.
Three programs, one platform
Each program applies the same pathway biology to a distinct unmet need in women's health.
Ovarian Cancer
Targeting YAP-driven high-grade serous ovarian cancer, which often begins in the fallopian tube.
Learn more →Fertility Preservation
Aiming to protect and restore ovarian function in young women undergoing cancer treatment.
Learn more →Cervical Cancer
Addressing YAP1-driven cervical cancer, including disease that arises independently of HPV.
Learn more →The same protein, two opposite roles
YAP drives tumor growth in gynecological cancers, yet is essential for healthy follicles in the ovary. Our approach is designed around this duality.
In cancer
Hyperactive nuclear YAP drives proliferation and survival of ovarian and cervical cancer cells. Our cancer programs aim to switch it off.
In the healthy ovary
Timely YAP activity in granulosa cells supports follicle development. Our fertility program aims to restore physiological signaling.
Our programs
Science and company-building, together
Hippo Biosciences pairs more than a decade of Hippo/YAP research with deep experience in biotech operations, capital markets, and partnerships.
Partner with us
We welcome conversations with scientists, clinicians, investors, and strategic partners who share our commitment to women's health.